Inquiry Basket
Loading ......
Glycated Albumin (GA) is formed through the non-enzymatic glycation of serum albumin and reflects average blood glucose levels over the preceding 2–3 weeks. Compared with HbA1c, GA responds more rapidly to changes in glycemic status and is particularly useful for monitoring short-term glucose fluctuations.
Fig. 1 Albumin binds with glucose and form glycated albumin
As a biomarker of intermediate-term glycemic control, GA has gained increasing attention in diabetes, diabetic complications, metabolic syndrome, and cardiometabolic disease research. Beyond its role as a glucose marker, accumulating evidence suggests that glycated albumin is associated with oxidative stress, inflammation, and vascular dysfunction, contributing to the progression of metabolic disorders.
Metabolic syndrome is characterized by a cluster of metabolic abnormalities, including central obesity, insulin resistance, dyslipidemia, hypertension, and impaired glucose metabolism. Among these factors, insulin resistance and postprandial hyperglycemia play central roles in disease progression.
Elevated GA levels have been associated with:
Unlike HbA1c, GA is more sensitive to postprandial glucose excursions and glycemic variability, making it particularly valuable for identifying early metabolic dysfunction before persistent hyperglycemia becomes evident.
✓ Early detection of impaired glucose metabolism
✓ Monitoring short-term glycemic changes
✓ Assessment of postprandial hyperglycemia
✓ Risk stratification in metabolic syndrome
✓ Evaluation of diabetes-related complications
Biomarker
Blood Glucose
Glycated Albumin (GA)
HbA1c
Reflects Glycemic Status
Hours
2–3 Weeks
2–3 Months
Because albumin has a shorter half-life than hemoglobin, glycated albumin provides a more responsive measure of recent glycemic control. In metabolic syndrome and prediabetes research, GA can provide valuable insight into postprandial hyperglycemia and glycemic variability before sustained elevations in HbA1c become apparent.
Accurate detection of glycated albumin remains technically challenging due to the high structural similarity between glycated and native albumin. In addition, glycation occurs at multiple sites and to varying degrees, generating heterogeneous molecular forms.
Key analytical challenges include:
High-quality antibodies capable of selectively recognizing glycation-associated epitopes are therefore essential for reliable glycated albumin assay development.
Creative Diagnostics offers a portfolio of monoclonal antibodies specifically developed for glycated human albumin detection and assay development.
Exceptional Specificity
Specific recognition of glycated human albumin
No detectable binding to deglycated or native albumin
Minimal cross-reactivity with other plasma proteins
Fig. 2 Selective Binding of A717-ScFv to Glycated Albumin
(DMABD-JX280)
Fig. 3 Competitive Binding of huA717-ScFv and A717-Fab to Glycated Albumin
(DMABD-JX273)
Defined Glycation-Dependent Epitopes
A717 recognizes glycation-associated epitopes generated during glucose modification of albumin, enabling selective detection of glycated albumin in biological samples.
Species Cross-Reactivity
A717 was optimized for human glycated albumin detection and exhibits cross-reactivity with mouse samples, while showing minimal reactivity toward albumins from other species.
Our premium antibody reagents are meticulously validated to support a wide range of platforms exploring the frontiers of metabolic health:
| Cat. No. | Product Name | Host | Application | |
| CABT-JXM17 | Anti-Human Glycated Albumin Mab, clone 2B22 | Mouse | ELISA | Inquiry |
| DMABD-JX280 | Anti-Human glycated albumin Mab, clone A717 | Mouse | ELISA, WB | Inquiry |
| DMABD-JX273 | Anti-Human glycated albumin Mab, clone HuA717 | Human | ELISA, WB | Inquiry |
Loading ......
